- Rating
- 2
- Confidence
- 3
- Informativeness
- 2
- Presentation
- 3
- Soundness
- 2
Read review
Paper summary
The authors propose Co-ADIOS, an extension of the ADIOS framework to the joint design of antibody cocktails that steer viral evolution towards less favourable variants. The problem is formulated as a Stackelberg evolutionary game, combining an inner viral evolution simulator with an outer cooperative co-evolutionary algorithm for antibody optimisation.
The framework is evaluated on two tasks: (I) considering both the design of new antibody pairs and (II) the optimisation of a complementary antibody for an existing therapeutic. The authors report improvements over myopic and non-cooperative baselines, together with an analysis of the resulting viral escape landscapes.
Critical strengths
-
I find the general motivation compelling. Optimising therapies while accounting for the evolutionary response they induce is an interesting and potentially important problem.
-
The framework is intuitive and reasonably well presented, and the extension to coordinated antibody combinations is well motivated.
-
The experiments show consistent improvements within the simulator, with multiple seeds, held-out evaluations, and useful analyses of the resulting escape landscapes.
Critical weaknesses
-
Overall, the central formulation and evolutionary shaping principle are inherited from ADIOS. The main extension consists of introducing cooperative co-evolution for antibody pairs (an interesting application), using an established optimisation technique. I am not entirely convinced that this constitutes a sufficiently substantial methodological contribution on its own.
-
Although the ablations are useful, I would have liked to see comparisons against stronger alternatives, particularly independently optimised ADIOS antibodies, compute-matched joint optimisation, and approaches optimising robustness across a fixed set of viral variants.
-
It is not entirely clear to me how much of the improvement comes specifically from complementary antibody behaviour rather than simply stronger or broader neutralisation.
Questions for authors
-
Q1: Can the authors compare against independently optimised ADIOS antibody pairs and a compute-matched joint optimiser, to better establish the contribution of cooperative co-evolution?
-
Q2: Can they compare against a robust optimisation baseline that targets a predefined collection of viral variants, rather than modelling cocktail-induced evolutionary trajectories?
-
Q3: Can the authors assess generalisation to another antigen or an independent binding/viral fitness model?
Should the authors address my questions I would be incliden towards weak acceptance, given the remaining doubt on methodological novelty
3 comments
Rebuttal (2/2)
W3: Complementary behaviour versus broader neutralisation
Two results demonstrate the complementary behaviour. First, the broad-binding baselines directly optimise for broad neutralisation, and Co-ADIOS outperforms them on every seed (W2 above). Second, the new Figure 6c compares the cocktail with each of its antibodies given alone at the full dose. If the gain came from one stronger antibody, that antibody would do as well on its own. Instead, the virus escapes each antibody faster when it is given alone, and the cocktail's held-out return exceeds that of its stronger antibody by on all 20 seeds. The new Figure I.1 (Appendix I) shows the escape landscape of each antibody of the Figure 6 cocktail given alone at the full dose: against the wildtype, 139 and 104 single substitutions raise viral activity, so each antibody alone leaves many escape routes open.
Q3: Another antigen or an independent model
We have repeated Scenario 1 on a second antigen, the SARS-CoV-2 receptor-binding domain (PDB 6XDG, new Appendix G). This also changes the viral fitness model, as the viral target is the real receptor, ACE2. Co-ADIOS outperforms the myopic, broad-binding and concatenated baselines on all 20 seeds and the independent ADIOS cocktail on 14/20 seeds, and matches the ADIOS single (, ). We think the last result is a limitation of the Absolut! binding simulator rather than of Co-ADIOS: 6XDG has two distinct epitopes, but under Absolut!'s lattice energy the second is seldom selected as an antibody's lowest-energy pose, so the two antibodies converge to the same site (Appendix D).
We have also tested a different model of viral evolution: re-scoring the influenza designs with an inner loop that carries 30 viruses between escape steps barely changes the results (new Appendix F). We are aware of the limitations of Absolut! and are building a higher-fidelity binding simulator, but this is a separate line of work and out of scope for this paper.
You mentioned that you would lean towards acceptance if we addressed your questions. We believe we have now addressed each of them, and we would be grateful if you would consider raising your score. If you have any remaining concerns, please let us know, and we will do our best to address them during the remaining discussion period, whether through clarification, further changes to the manuscript or additional experiments.
Rebuttal Follow-up
Thank you again for your constructive review. As the discussion period is ending soon, we wanted to briefly follow up on our rebuttal.
We have conducted all three sets of experiments you requested: independently optimised and compute-matched baselines (Q1), broad-binding baselines that target a collection of viral variants (Q2), and evaluation on a second antigen (Q3), alongside robustness checks on the evolutionary dynamics. The new results provide further evidence of Co-ADIOS's advantages over the baselines.
We would be very grateful to know whether these additions have addressed your concerns and, if so, whether you would consider updating your score before the discussion closes.
Thank you again for your time and feedback!
Rebuttal (1/2)
Thank you for your review! We are glad you find the motivation compelling and the framework well presented, and that you value our explainability section on the escape landscapes. We have run all experiments you asked for in Q1 to Q3 and updated the manuscript with the new results. The details are below, and all new text in the revised manuscript is in blue.
W1: Novel methodological contribution
We agree that the shaping principle and the Stackelberg framing come from ADIOS, and that cooperative co-evolution is an established technique. However, we believe extending ADIOS to antibody cocktails is both important and far from a direct application. It is important because combination therapies are the standard way to limit escape in evolving pathogens, from HIV to COVID-19 (Section 1), yet to our knowledge no opponent-shaping method exists for designing them. It also required new components beyond a different optimiser:
W2 / Q1 / Q2: Stronger baselines at matched budget
We have added all three baselines you suggested, and every baseline is now run with the same budget of binding evaluations as Co-ADIOS (Table E.2 lists the settings and budget of every method):
At matched budget on influenza, Co-ADIOS outperforms the independent ADIOS cocktail by +0.025 (16/20 seeds), the concatenated cocktail by +0.057 (19/20), the broad-binding cocktail by +0.135 (20/20) and the broad-binding single by +0.167 (20/20) (Figure 4d). The broad-binding baselines work well against the wildtype, but the virus escapes them within a few steps (Figure 4a), so most of the improvement comes from accounting for the viral trajectory the cocktail induces. In Scenario 2, the Co-ADIOS complement also outperforms the broad-binding complement by +0.10 on all 20 seeds (Figure 5c).
(continued below)